BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2862629)

  • 1. [Medullary cancer of the thyroid in type IIB multiple endocrine neoplasia. Uptake of meta-iodo-benzylguanidine labeled with iodine 131].
    Chamouard P; Jouin H; Varra A; Weill JP; Constantinesco A
    Presse Med; 1985 Jun; 14(25):1387. PubMed ID: 2862629
    [No Abstract]   [Full Text] [Related]  

  • 2. [Detection by scintigraphy with meta-iodobenzylguanidine of a subclinical tumoral thyroid nodule in Sipple's syndrome].
    Gallet M; Penet D; Berthet C; Kepenekian G; Fleury M; Lestaevel M
    Presse Med; 1986 Jul 5-12; 15(27):1282. PubMed ID: 2876419
    [No Abstract]   [Full Text] [Related]  

  • 3. [Localization of medullary cancer of the thyroid gland by scintigraphy using meta-iodo-benzylguanidine].
    Getin F; Rohmer V; Saint Andre JP; Jallet P; Bigorgne JC
    Presse Med; 1985 Mar; 14(10):597. PubMed ID: 3157942
    [No Abstract]   [Full Text] [Related]  

  • 4. [Medullary thyroid cancer may take up meta-iodobenzylguanidine].
    Krempf M; Chatal JF; Charbonnel B
    Presse Med; 1985 Sep; 14(29):1560-1. PubMed ID: 2932697
    [No Abstract]   [Full Text] [Related]  

  • 5. Imaging of medullary thyroid cancer with 131I-MIBG.
    Endo K; Shiomi K; Kasagi K; Konishi J; Torizuka K; Nakao K; Tanimura H
    Lancet; 1984 Jul; 2(8396):233. PubMed ID: 6146795
    [No Abstract]   [Full Text] [Related]  

  • 6. Medullary thyroid carcinoma: localization of a mediastinal metastasis with I-131 MIBG.
    Laflamme L; Taillefer R; Duranceau A; Verdy M; Schürch W
    Clin Nucl Med; 1988 Aug; 13(8):577-9. PubMed ID: 2901928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine.
    Poston GJ; Thomas AM; Macdonald DW; Karvounaris D; Henderson BL; George P; Lynn JA; Lavender JP
    Nucl Med Commun; 1986 Apr; 7(4):215-21. PubMed ID: 2873544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin.
    Keeling CA; Basso LV
    Clin Nucl Med; 1988 Apr; 13(4):260-3. PubMed ID: 2897264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [I-131-meta-iodobenzylguanidine and multiple endocrine adenomatosis type II].
    Simó R; Mesa J
    Med Clin (Barc); 1987 Dec; 89(20):888. PubMed ID: 2896282
    [No Abstract]   [Full Text] [Related]  

  • 10. Imaging of medullary thyroid carcinoma and hyperfunctioning adrenal medulla using iodine-131 metaiodobenzylguanidine.
    Ansari AN; Siegel ME; DeQuattro V; Gazarian LH
    J Nucl Med; 1986 Dec; 27(12):1858-60. PubMed ID: 2878066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and therapeutic potential of new radiopharmaceutical agents in medullary thyroid carcinoma.
    Troncone L; Rufini V; De Rosa G; Testa A
    Henry Ford Hosp Med J; 1989; 37(3-4):178-84. PubMed ID: 2576959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
    Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
    J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid uptake of MIBG in Sipple's syndrome.
    Perdrisot R; Rohmer V; Lejeune JJ; Bigorgne JC; Jallet P
    Eur J Nucl Med; 1988; 14(1):37-8. PubMed ID: 2898364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for pheochromocytoma in the MEN 2 syndrome.
    Kotzerke J; Stibane C; Dralle H; Wiese H; Burchert W
    Henry Ford Hosp Med J; 1989; 37(3-4):129-31. PubMed ID: 2576945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pitfall of Sipple's syndrome diagnosis by 131I-metaiodobenzylguanidine (MIBG).
    Talbot JN; Coutris G; Moulonguet M; Hoang C; Perniceni T; Milhaud G
    J Nucl Med Allied Sci; 1987; 31(4):337-40. PubMed ID: 2895168
    [No Abstract]   [Full Text] [Related]  

  • 16. Sipple's syndrome with liver tumors examined by iodine-131 MIBG and technetium-99m(V)-DMSA.
    Ohta H; Endo K; Fujita T; Koizumi M; Konishi J; Maki A; Mori K; Ozawa K; Inoue G; Nakano Y
    J Nucl Med; 1988 Jun; 29(6):1130-5. PubMed ID: 2897436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of different scintigraphic techniques to the management of medullary thyroid carcinoma.
    Sandrock D; Blossey HC; Steinroeder M; Munz DL
    Henry Ford Hosp Med J; 1989; 37(3-4):173-4. PubMed ID: 2576957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
    Verga U; Muratori F; Di Sacco G; Banfi F; Libroia A
    Henry Ford Hosp Med J; 1989; 37(3-4):175-7. PubMed ID: 2576958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of metastases from medullary thyroid carcinoma using different methods.
    Cabezas RC; Berna L; Estorch M; Carrio I; Garcia-Ameijeiras A
    Henry Ford Hosp Med J; 1989; 37(3-4):169-72. PubMed ID: 2639132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic medullary thyroid cancer: localization with iodine-131 metaiodobenzylguanidine.
    Sone T; Fukunaga M; Otsuka N; Morita R; Muranaka A; Yanagimoto S; Tomomitsu T; Nakayama H; Harada T
    J Nucl Med; 1985 Jun; 26(6):604-8. PubMed ID: 3158726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.